Atlas Trials

Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Clinical trial NCT05537571 · COMPLETED

Trial details

NCT number
NCT05537571
Sponsor
Silence Therapeutics plc
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Cardiovascular DiseasesAtherosclerosisLipoprotein(a)
Start date
2022-12-13
Primary completion
2024-01-11
Enrollment
180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.